Literature DB >> 17599771

Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model.

Lynne Shand1, Mark Lunt, Svetlana Nihtyanova, Mansour Hoseini, Alan Silman, Carol M Black, Christopher P Denton.   

Abstract

OBJECTIVE: To explore the relationship between changes in the severity of skin disease and morbidity and mortality in patients with diffuse cutaneous systemic sclerosis (dcSSc).
METHODS: From a large single-center cohort, we identified 225 patients with dcSSc for whom serial clinical information was available from within 24 months of the onset of the first non-Raynaud's phenomenon manifestation of SSc. The end points analyzed included death and heart, lung, kidney, and gastrointestinal tract involvement. Latent linear trajectory modeling (LTM) was applied to identify patients with a similar trajectory of modified Rodnan skin thickness score (MRSS) changes over the first 3 years of followup. Clinical outcomes were compared between 3 different LTM subgroups.
RESULTS: LTM permitted classification of 131 patients (58%) into 1 of 3 subgroups with different skin score trajectories. Survival was lowest in the subgroup of patients who had a high baseline skin score and experienced little improvement during followup (P = 0.003). However, the frequency of clinical end points was similar in the subgroup with the most favorable trajectory (i.e., a low initial MRSS and subsequent improvement) and the subgroup with a high baseline MRSS and no improvement. Interestingly, the end point frequency was greatest in the subgroup with a high initial MRSS and subsequent improvement, suggesting that sustained severe skin disease does not necessarily predict the number of visceral complications, and that the relationship between the skin score and internal organ involvement in dcSSc is more complex than previously thought.
CONCLUSION: Although mortality was highest among patients with the worst skin-related outcomes, no simple relationship between burden of disease and change in skin score was observed.

Entities:  

Mesh:

Year:  2007        PMID: 17599771     DOI: 10.1002/art.22721

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  59 in total

Review 1.  Evidence-based management of rapidly progressing systemic sclerosis.

Authors:  Dinesh Khanna; Christopher P Denton
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-06       Impact factor: 4.098

Review 2.  [Clinical risk-adapted therapies in systemic sclerosis].

Authors:  G Riemekasten; D Dragun
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372

3.  Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Authors:  Giuseppina Stifano; Thierry Sornasse; Lisa M Rice; Leo Na; Haiyin Chen-Harris; Dinesh Khanna; Angelika Jahreis; Yuqing Zhang; Jeff Siegel; Robert Lafyatis
Journal:  Arthritis Rheumatol       Date:  2018-06       Impact factor: 10.995

4.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

Review 5.  Personalized medicine in systemic sclerosis: facts and promises.

Authors:  Rucsandra Dobrota; Carina Mihai; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

Review 6.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 7.  Cytokines in the immunopathology of systemic sclerosis.

Authors:  Jasmin Raja; Christopher Paul Denton
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

8.  Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma.

Authors:  Robyn T Domsic; Tatiana Rodriguez-Reyna; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  Ann Rheum Dis       Date:  2010-08-02       Impact factor: 19.103

9.  Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis.

Authors:  Dinesh Khanna; Daniel E Furst; Philip J Clements; Yannick Allanore; Murray Baron; Lazlo Czirjak; Oliver Distler; Ivan Foeldvari; Masataka Kuwana; Marco Matucci-Cerinic; Maureen Mayes; Thomas Medsger; Peter A Merkel; Janet E Pope; James R Seibold; Virginia Steen; Wendy Stevens; Christopher P Denton
Journal:  J Scleroderma Relat Disord       Date:  2017 Jan-Apr

Review 10.  [Systemic sclerosis. Objectives for the treatment].

Authors:  B Maurer; M Walder; R E Gay; S Gay; O Distler
Journal:  Z Rheumatol       Date:  2009-02       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.